Q1 25 EPS
$-1.58
MISS 23.75%
Est. $-1.28
Q1 25 Revenue
$865,000
MISS 85.50%
Est. $6.0M
vs S&P Since Q1 25
+33.1%
BEATING MARKET
CRSP +63.0% vs S&P +29.9%
Market Reaction
Did CRSP Beat Earnings? Q1 2025 Results
CRISPR Therapeutics delivered a sharply disappointing first quarter, missing on both the top and bottom lines as the gene editing company continues to burn cash across a busy pipeline. The company posted an EPS loss of $1.58, missing the consensus es… Read more CRISPR Therapeutics delivered a sharply disappointing first quarter, missing on both the top and bottom lines as the gene editing company continues to burn cash across a busy pipeline. The company posted an EPS loss of $1.58, missing the consensus estimate of $1.28 by 23.75%, while revenue of just $865,000, composed entirely of grant income with no collaboration revenue recognized, fell 85.50% short of the $5.96 million Wall Street had expected, even as that figure represented 71.6% growth year-over-year. The net loss widened to $136 million from $116.59 million a year earlier, driven in part by higher collaboration expenses tied to CASGEVY and in vivo HSC editing programs. With significant short interest riding on the outcome, the headline numbers were softened by a genuine clinical bright spot: CTX310 demonstrated dose-dependent LDL and triglyceride reductions of up to 81% and 82%, respectively, across its first 10 patients. Management guided for growing CASGEVY patient initiations through 2025 and flagged CTX320 top-line data as a near-term catalyst expected in Q2.
Key Takeaways
- • Positive Phase 1 clinical data from CTX310 targeting ANGPTL3 for cardiovascular disease
- • Continued CASGEVY commercial rollout with more than 65 authorized treatment centers activated globally
- • Approximately 90 patients have had cells collected across all regions for CASGEVY
- • New reimbursement agreements secured in NHS England, Wales, Austria, and UAE Emirates
- • Lower R&D expenses driven by decreased employee-related and stock-based compensation costs
CRSP YoY Financials
Q1 2025 vs Q1 2024, source: SEC Filings
CRSP Revenue by Segment
With YoY comparisons, source: SEC Filings
“CRISPR Therapeutics remains focused on executing our strategic priorities and advancing our portfolio of innovative therapies. We are highly encouraged by the initial data from our Phase 1 trial for CTX310, which demonstrates the power of our in vivo gene editing platform to deliver paradigm changing medicines to patients with serious cardiovascular disease.”
— Samarth Kulkarni, Q1 2025 Earnings Press Release
CRSP Earnings Trends
CRSP vs Market 30 Day Price Reactions
30-day stock return vs benchmark after each earnings
CRSP EPS Trend
Earnings per share: estimate vs actual
CRSP Revenue Trend
Quarterly revenue: estimate vs actual
CRSP Quarterly Results
5 quarters of earnings data
| Quarter | EPS Est. | EPS Act. | Surprise | Revenue | Rev. Surprise |
|---|---|---|---|---|---|
| Q1 26 MISS | $-1.23 | $-1.28 | -3.68% | $1.5M | -65.73% |
| Q4 25 MISS FY | $-1.23 | $-1.37 | -11.67% | $864,000 | -78.51% |
| FY Full Year | $-6.17 | $-6.47 | -4.91% | $3.5M | -42.66% |
| Q3 25 BEAT | $-1.29 | $-1.17 | +9.23% | $889,000 | -90.07% |
| Q2 25 MISS | $-1.40 | $-2.40 | -71.55% | $892,000 | -86.15% |
| Q1 25 MISS | $-1.28 | $-1.58 | -23.75% | $865,000 | -85.50% |